We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00100425
First Posted: December 31, 2004
Last Update Posted: January 21, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
VA Office of Research and Development
December 30, 2004
December 31, 2004
January 21, 2009
September 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00100425 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome
Central Nervous System Modulation of Visceral Pain in Persian Gulf War Syndrome
The purpose of this study is to provide new information and to determine which kinds of brief, tolerable, experimental pain are affected by the drugs being studied in patients with irritable bowel syndrome, a disease that causes chronic abdominal pain. The effects of dextromethorphan, naloxone, and fentanyl on experimental pain stimuli will be tested in these studies to better understand what causes irritable bowel syndrome.
Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Diagnostic
Irritable Bowel Syndrome
Procedure: Viceral Perception Testing
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided
  • Patients with irritable bowel syndrome and healthy pain-free individuals (as controls) will be studied.
  • No medical condition that would contraindicate use of dextromethorphan, fentanyl or naloxone.
Sexes Eligible for Study: All
18 Years to 72 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00100425
CADE-ARCD2
Not Provided
Not Provided
Not Provided
Not Provided
VA Office of Research and Development
Not Provided
Not Provided
VA Office of Research and Development
December 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP